Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

Abstract

Hereditary anemia has various manifestations, such as sickle cell disease (SCD), Fanconi anemia, glucose-6-phosphate dehydrogenase deficiency (G6PDD), and thalassemia. The available management strategies for these disorders are still unsatisfactory and do not eliminate the main causes. As genetic aberrations are the main causes of all forms of hereditary anemia, the optimal approach involves repairing the defective gene, possibly through the transplantation of normal hematopoietic stem cells (HSCs) from a normal matching donor or through gene therapy approaches (either in vivo or ex vivo) to correct the patient’s HSCs. To clearly illustrate the importance of cell and gene therapy in hereditary anemia, this paper provides a review of the genetic aberration, epidemiology, clinical features, current management, and cell and gene therapy endeavors related to SCD, thalassemia, Fanconi anemia, and G6PDD. Moreover, we expound the future research direction of HSC derivation from induced pluripotent stem cells (iPSCs), strategies to edit HSCs, gene therapy risk mitigation, and their clinical perspectives. In conclusion, gene-corrected hematopoietic stem cell transplantation has promising outcomes for SCD, Fanconi anemia, and thalassemia, and it may overcome the limitation of the source of allogenic bone marrow transplantation.

Cellular enlargement - A new hallmark of aging?

“…A healthy blood system requires HSCs to balance and maintain both these abilities, which decline with age. This leads to stem cell exhaustion and biased lineage differentiation ( Yamashita and Iwama, 2022 ), which can contribute to the development of anemia, leukemia and a compromised immune system ( Dykstra and de Haan, 2008 ; Hill et al, 2017 ; Chen et al, 2019 ; Chopra and Bohlander, 2019 ; Anurogo et al, 2021 ).…”

Terapi Sel Punca dan Tata Laksana Covid-19

“…20 Terapi berbasis sel punca didefinisikan sebagai pengobatan apa pun untuk penyakit atau kondisi medis yang pada dasarnya melibatkan penggunaan semua jenis sel punca manusia yang layak, termasuk sel punca embrionik atau embryonic stem cells (ESC), iPSC, dan sel punca dewasa untuk terapi autologus dan alogenik. 21 Sel punca menawarkan solusi sempurna ketika ada kebutuhan untuk transplantasi jaringan dan organ melalui kemampuannya untuk berdiferensiasi menjadi jenis sel spesifik yang diperlukan untuk perbaikan jaringan yang sakit. 22 Potensi penerapan terapi berbasis sel punca ini termasuk terapi untuk penyakit neurodegeneratif, penyakit mata, diabetes, dan penyakit pernapasan seperti Covid-19 dan ARDS.…”

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

“…A broader definition considers oligonucleotide- [ 2 ] and RNA interference (RNAi)-based gene silencing [ 3 ], immunotherapy, especially cancer immunotherapy, and vaccine development as gene therapy [ 4 ]. More recently, stem cell technologies [ 5 ], chimeric antigen receptor (CAR) T-cell therapy [ 6 ], and Clustered Regularly Interspaced Short Palindromic (CRISPR) [ 7 ], providing unprecedent possibilities for gene replacement and gene editing, have also received gene therapy status.…”